Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark. Construction of the new laboratories has already started and the new facility, to be named the Diabetes Research House, will open in early 2016. The Diabetes Research
Novo Nordisk has received approval from US regulatory body, the Food and Drug Administration (FDA) for their haemophilia A drug. The regulatory board have approved the Novo Nordisk’s Biologics License Application for Novoeight (turoctocog alfa), a third-generation recombinant coagulation factor VIII.
European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted marketing authorisations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.
Novo Nordisk has revealed plans to expand their treatment for diabetes in emerging markets by employing roughly 1,000 additional employees over the next two years. Some of the emerging markets that Novo Nordisk are planning to expand in include Egypt, Vietnam, Colombia, Malaysia, Ukraine and Indonesia. As the pharmaceutical market in Europe, for example, slows
Enlight Biosciences LLC announced yesterday that they have formed new partnerships with AstraZeneca and Novo Nordisk. As partners, AstraZeneca and Novo Nordisk will have the chance to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight is a unique entrepreneurial partnership with major pharmaceutical companies and leading
Novo Nordisk has filed two marketing authorisation applications for approval to the European Medical Agency for their ultra long-acting insulin Degludec and insulin combination analogue DegludecPlus. The submissions are based on results from the BEGIN and BOOST clinical trial programmes which involved nearly 10,000 type 1 and type 2 diabetes patients. Data from the trials
A study has shown that Novo Nordisk’s ultra-long-acting insulin degludec, a investigational basal insulin, can provide control of blood sugar in diabetics as good as rival drug Lantus from Sanofi, while allowing for more flexible dosing. Insulin degludec achieved significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily
